BACKGROUND: Few trials have investigated late preemptive conversion of kidney transplant patients from a calcineurin inhibitor (CNI) to an mTOR inhibitor. METHODS: In an open-label, 12-month, prospective, randomized, parallel-group study, maintenance kidney transplant patients (>6 months post-transplant) either switched from CNI to everolimus or continued their current CNI regimen. Patients who completed the core study were followed to 5 years post-randomization. RESULTS: Of 93 randomized patients, 78 completed the core study and 67 attended the final 60-month study visit. Mean time post-transplant at baseline was 82.6 months and 70.5 months in the everolimus and CNI groups, respectively. At month 60, adjusted mean eGFR (Nankivell) was 63.0 (95% CI 57.8, 68.2) mL/min/1.73 m(2) in the everolimus group versus 57.9 (95% CI 52.6, 63.1) mL/min/1.73 m(2) in the CNI group, a difference of 5.1 (95% CI -0.6, 10.8) mL/min/1.73 m(2) (p = 0.076). Among patients who remained on randomized study drug at month 60, mean eGFR (Nankivell) was 71.6 (95% CI 64.2, 79.0) mL/min/1.73 m(2) in everolimus-treated patients (n = 21) versus 60.6 (95% CI 55.1, 66.1) mL/min/1.73 m(2) in CNI-treated patients (n = 29) (mean difference 11.0; 95% CI 3.6, 18.5 mL/min/1.73 m(2); p = 0.005). No cases of BPAR occurred from randomization to month 60 in either group. Graft loss occurred in three everolimus-treated patients and one CNI-treated patient. No unexpected safety concerns were observed in either group. CONCLUSION: Late preemptive conversion of maintenance kidney transplant patients from CNI to everolimus may be associated with improved long-term renal function and preserves immunosuppressive efficacy. Patient numbers were low, but these findings merit further investigation.
BACKGROUND: Few trials have investigated late preemptive conversion of kidney transplant patients from a calcineurin inhibitor (CNI) to an mTOR inhibitor. METHODS: In an open-label, 12-month, prospective, randomized, parallel-group study, maintenance kidney transplant patients (>6 months post-transplant) either switched from CNI to everolimus or continued their current CNI regimen. Patients who completed the core study were followed to 5 years post-randomization. RESULTS: Of 93 randomized patients, 78 completed the core study and 67 attended the final 60-month study visit. Mean time post-transplant at baseline was 82.6 months and 70.5 months in the everolimus and CNI groups, respectively. At month 60, adjusted mean eGFR (Nankivell) was 63.0 (95% CI 57.8, 68.2) mL/min/1.73 m(2) in the everolimus group versus 57.9 (95% CI 52.6, 63.1) mL/min/1.73 m(2) in the CNI group, a difference of 5.1 (95% CI -0.6, 10.8) mL/min/1.73 m(2) (p = 0.076). Among patients who remained on randomized study drug at month 60, mean eGFR (Nankivell) was 71.6 (95% CI 64.2, 79.0) mL/min/1.73 m(2) in everolimus-treated patients (n = 21) versus 60.6 (95% CI 55.1, 66.1) mL/min/1.73 m(2) in CNI-treated patients (n = 29) (mean difference 11.0; 95% CI 3.6, 18.5 mL/min/1.73 m(2); p = 0.005). No cases of BPAR occurred from randomization to month 60 in either group. Graft loss occurred in three everolimus-treated patients and one CNI-treated patient. No unexpected safety concerns were observed in either group. CONCLUSION: Late preemptive conversion of maintenance kidney transplant patients from CNI to everolimus may be associated with improved long-term renal function and preserves immunosuppressive efficacy. Patient numbers were low, but these findings merit further investigation.
Authors: H Tedesco Silva; D Cibrik; T Johnston; E Lackova; K Mange; C Panis; R Walker; Z Wang; G Zibari; Y S Kim Journal: Am J Transplant Date: 2010-04-28 Impact factor: 8.086
Authors: H T Silva; C R Felipe; V D Garcia; E D Neto; M A Filho; F L C Contieri; D D B M de Carvalho; J O M Pestana Journal: Am J Transplant Date: 2013-10-30 Impact factor: 8.086
Authors: Markus Guba; Johann Pratschke; Christian Hugo; Bernhard K Krämer; Constanze Nohr-Westphal; Jens Brockmann; Joachim Andrassy; Petra Reinke; Katharina Pressmar; Oliver Hakenberg; Michael Fischereder; Andreas Pascher; Wolf-Dieter Illner; Bernhard Banas; Karl-Walter Jauch Journal: Transplantation Date: 2010-07-27 Impact factor: 4.939
Authors: Y Lebranchu; A Thierry; O Toupance; P F Westeel; I Etienne; E Thervet; B Moulin; T Frouget; Y Le Meur; D Glotz; A-E Heng; C Onno; M Buchler; S Girardot-Seguin; B Hurault de Ligny Journal: Am J Transplant Date: 2009-05 Impact factor: 8.086
Authors: Laetitia Albano; François Berthoux; Marie-Christine Moal; Lionel Rostaing; Christophe Legendre; Robert Genin; Olivier Toupance; Bruno Moulin; Pierre Merville; Jean-Philippe Rerolle; François Bayle; Pierre François Westeel; Denis Glotz; Niloufar Kossari; Nicole Lefrançois; Bernard Charpentier; Anne-Sandrine Blanc; Fabienne Di Giambattista; Jacques Dantal Journal: Transplantation Date: 2009-07-15 Impact factor: 4.939
Authors: Stefan Vitko; Helio Tedesco; Josette Eris; Julio Pascual; John Whelchel; John C Magee; Scott Campbell; Giovanni Civati; Bernard Bourbigot; Gentil Alves Filho; John Leone; Valter Duro Garcia; Paolo Rigotti; Ronaldo Esmeraldo; Vincenzo Cambi; Tomas Haas; Annette Jappe; Peter Bernhardt; Johanna Geissler; Nathalie Cretin Journal: Am J Transplant Date: 2004-04 Impact factor: 8.086
Authors: Akinlolu O Ojo; Philip J Held; Friedrich K Port; Robert A Wolfe; Alan B Leichtman; Eric W Young; Julie Arndorfer; Laura Christensen; Robert M Merion Journal: N Engl J Med Date: 2003-09-04 Impact factor: 91.245
Authors: Samir G Mallat; Bassem Y Tanios; Houssam S Itani; Tamara Lotfi; Ciaran McMullan; Steven Gabardi; Elie A Akl; Jamil R Azzi Journal: Clin J Am Soc Nephrol Date: 2017-06-02 Impact factor: 8.237
Authors: Claudia Sommerer; Barbara Suwelack; Duska Dragun; Peter Schenker; Ingeborg A Hauser; Björn Nashan; Friedrich Thaiss Journal: Trials Date: 2016-02-17 Impact factor: 2.279
Authors: Gerold Thölking; Nils Hendrik Gillhaus; Katharina Schütte-Nütgen; Hermann Pavenstädt; Raphael Koch; Barbara Suwelack; Stefan Reuter Journal: J Clin Med Date: 2020-01-23 Impact factor: 4.241